(2R,3R)-3-(methoxymethoxy)-1-(4-methoxyphenyl)-4-oxoazetidin-2-formaldehyde | 1252877-44-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: (2R,3R)-3-(methoxymethoxy)-1-(4-methoxyphenyl)-4-oxoazetidin-2-formaldehyde
• 英文别名: (2R,3R)-3-(methoxymethoxy)-1-(4-methoxyphenyl)-4-oxoazetidine-2-carbaldehyde；(2R,3R)-3-(methoxymethoxy)-1-(4-methoxyphenyl)-4-oxoazetidin-2-carbaldehyde
• CAS: 1252877-44-3
• 化学式: C₁₃H₁₅NO₅
• 分子量: 265.266
• InChiKey: LVLSCDPVRWEHQS-NWDGAFQWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2R,3R)-3-(methoxymethoxy)-1-(4-methoxyphenyl)-4-oxoazetidin-2-formaldehyde 在 Crabtree's catalyst 、 氢气 、 双(三甲基硅烷基)氨基钾 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 (3R)-4-(2-cyclobutylethyl)-3-(methoxymethoxy)-1-(4-methoxyphenyl)azetidin-2-one
  参考文献：
  名称：

  TW2016/9654

  摘要：

  公开号：
• 作为产物：
  描述：

  (3R,4S)-4-[(1S)-1,2-dihydroxyethyl]-3-(methoxymethoxy)-1-(4-methoxyphenyl)azetidin-2-one 在 sodium periodate 、 碳酸氢钠 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 1.0h， 以1.8 g的产率得到(2R,3R)-3-(methoxymethoxy)-1-(4-methoxyphenyl)-4-oxoazetidin-2-formaldehyde
  参考文献：
  名称：

  PYRIDINE DERIVATIVES

  摘要：

  公开号：

  EP3228616B1

文献信息

• Metal-Catalyzed Cycloisomerization and Tandem Oxycyclization/Hydroxylation of Alkynols: Synthesis of Nonfused, Spiranic and Fused Oxabicyclic β-Lactams
  作者：Benito Alcaide、Pedro Almendros、Teresa Martínez del Campo、Rocío Carrascosa

  DOI：10.1002/ejoc.201000710

  日期：2010.9

  2-Azetidinone-tethered alkynols, readily prepared from the corresponding aldehydes or ketones, were used as starting materials for the oxycyclization reaction catalyzed by precious metals. AgOAc exclusively affords dihydrofurans, methylenetetrahydrofurans, or methylenetetrahydro-2H-pyrans through specific 5-endo, 5-exo, or 6-exo pathways, respectively. Interestingly, in the presence of a catalytic amount of Pt"

  2-氮杂环丁酮链炔醇，很容易从相应的醛或酮制备，被用作贵金属催化氧环化反应的原料。AgOAc 分别通过特定的 5-endo、5-exo 或 6-exo 途径专门提供二氢呋喃、亚甲基四氢呋喃或亚甲基四氢-2H-吡喃。有趣的是，在催化量的 Pt" 或 Au III 盐的存在下，环化反应优先通过炔醇的串联氧环化/羟基化发生，以中等至高产率提供各种非稠合、螺旋和稠合氧杂双环 β-内酰胺。此外，已经观察到可以完成串联金催化的甲氧基甲基炔基醚的环醚化/羟基化。
• PYRIDINE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP3150581A1

  公开（公告）日：2017-04-05

  The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-[4-(substituted pyridine)-2-yl]methyl}-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.

  本发明要解决的问题是提供一种适用于药物组合物的化合物，特别是一种用于治疗夜尿症的药物组合物。 本发明者假定，抑制胎盘亮氨酸氨肽酶（P-LAP）（即裂解 AVP 的氨肽酶）的夜间活性将维持和/或增加内源性 AVP 水平，从而增强抗利尿作用，这将有助于减少夜间排尿次数，并对抑制 P-LAP 的化合物进行了广泛研究。 结果，本发明人发现(2R)-3-氨基-2-[4-（取代的吡啶）-2-基]甲基}-2-羟基丙酸衍生物具有极佳的 P-LAP 抑制活性。本发明者评估了水负荷大鼠的抗利尿作用，发现这些化合物通过抑制 P-LAP 增加了内源性 AVP 水平，从而减少了尿量。因此，本发明提供的化合物有望用作基于 P-LAP 抑制作用的夜尿症治疗剂。
• Pyridine derivatives
  申请人：Astellas Pharma Inc.

  公开号：US10005762B2

  公开（公告）日：2018-06-26

  The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically an agent for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-(pyridylmethyl)-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.

  本发明要解决的问题是提供一种适用于药物组合物的化合物，特别是一种治疗夜尿症的药物。 本发明者假定，抑制胎盘亮氨酸氨肽酶（P-LAP）（即裂解 AVP 的氨肽酶）的夜间活性将维持和/或增加内源性 AVP 水平，从而增强抗利尿作用，这将有助于减少夜间排尿次数，并对抑制 P-LAP 的化合物进行了广泛研究。结果，本发明人发现(2R)-3-氨基-2-(吡啶基甲基)-2-羟基丙酸衍生物具有极佳的 P-LAP 抑制活性。本发明者评估了水负荷大鼠的抗利尿作用，发现这些化合物通过抑制 P-LAP 增加了内源性 AVP 水平，从而减少了尿量。因此，本发明提供的化合物有望用作基于 P-LAP 抑制作用的夜尿症治疗剂。
• Bicyclic pyridine compound
  申请人：Astellas Pharma Inc.

  公开号：US10023583B2

  公开（公告）日：2018-07-17

  The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-(bi-cyclic pyridylmethyl)-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.

  本发明要解决的问题是提供一种适用于药物组合物的化合物，特别是一种用于治疗夜尿症的药物组合物。 本发明者假定，抑制胎盘亮氨酸氨肽酶（P-LAP）（即能裂解 AVP 的氨肽酶）的夜间活性将维持和/或增加内源性 AVP 水平，从而增强抗利尿作用，这将有助于减少夜间排尿次数，并对抑制 P-LAP 的化合物进行了广泛研究。结果，本发明人发现(2R)-3-氨基-2-（双环吡啶基甲基）-2-羟基丙酸衍生物具有极佳的 P-LAP 抑制活性。本发明者评估了水负荷大鼠的抗利尿作用，发现这些化合物通过抑制 P-LAP 增加了内源性 AVP 水平，从而减少了尿量。因此，本发明提供的化合物有望用作基于 P-LAP 抑制作用的夜尿症治疗剂。
• Pyridine derivative
  申请人：Astellas Pharma Inc.

  公开号：US10059720B2

  公开（公告）日：2018-08-28

  The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-[4-(substituted pyridine)-2-yl]methyl}-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.

  本发明要解决的问题是提供一种适用于药物组合物的化合物，特别是一种用于治疗夜尿症的药物组合物。 本发明者假定，抑制胎盘亮氨酸氨肽酶（P-LAP）（即能裂解 AVP 的氨肽酶）的夜间活性将维持和/或增加内源性 AVP 水平，从而增强抗利尿作用，这将有助于减少夜间排尿次数，并对抑制 P-LAP 的化合物进行了广泛研究。 结果，本发明人发现(2R)-3-氨基-2-[4-（取代的吡啶）-2-基]甲基}-2-羟基丙酸衍生物具有极佳的 P-LAP 抑制活性。本发明者评估了水负荷大鼠的抗利尿作用，发现这些化合物通过抑制 P-LAP 增加了内源性 AVP 水平，从而减少了尿量。因此，本发明提供的化合物有望用作基于 P-LAP 抑制作用的夜尿症治疗剂。